Eli Lilly’s recent success largely centers on the impressive sales of two drugs, Mounjaro and Zepbound, both of which target the highly lucrative diabetes and weight-loss markets. Approved for diabetes in 2022, Mounjaro quickly became… Read More »Eli Lilly